GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (NYSE:PFE) » Definitions » Gross Margin %

Pfizer (Pfizer) Gross Margin %

: 46.92% (As of Dec. 2023)
View and export this data going back to 1951. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. Pfizer's Gross Profit for the three months ended in Dec. 2023 was $6,686 Mil. Pfizer's Revenue for the three months ended in Dec. 2023 was $14,249 Mil. Therefore, Pfizer's Gross Margin % for the quarter that ended in Dec. 2023 was 46.92%.

Warning Sign:

Pfizer Inc gross margin has been in long-term decline. The average rate of decline per year is -6.6%.


The historical rank and industry rank for Pfizer's Gross Margin % or its related term are showing as below:

PFE' s Gross Margin % Range Over the Past 10 Years
Min: 57.34   Med: 78.31   Max: 80.69
Current: 57.34


During the past 13 years, the highest Gross Margin % of Pfizer was 80.69%. The lowest was 57.34%. And the median was 78.31%.

PFE's Gross Margin % is ranked better than
67.81% of 991 companies
in the Drug Manufacturers industry
Industry Median: 46.88 vs PFE: 57.34

Pfizer had a gross margin of 46.92% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Pfizer was -6.60% per year.


Pfizer Gross Margin % Historical Data

The historical data trend for Pfizer's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 80.31 79.63 62.08 65.77 57.34

Pfizer Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.28 73.27 74.58 29.95 46.92

Competitive Comparison

For the Drug Manufacturers - General subindustry, Pfizer's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer Gross Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Pfizer's Gross Margin % falls into.



Pfizer Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Pfizer's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=33542 / 58496
=(Revenue - Cost of Goods Sold) / Revenue
=(58496 - 24954) / 58496
=57.34 %

Pfizer's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=6686 / 14249
=(Revenue - Cost of Goods Sold) / Revenue
=(14249 - 7563) / 14249
=46.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Pfizer  (NYSE:PFE) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Pfizer had a gross margin of 46.92% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Pfizer Gross Margin % Related Terms

Thank you for viewing the detailed overview of Pfizer's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer (Pfizer) Business Description

Address
66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Executives
Scott Gottlieb director MOLECULAR INSIGHT PHARMACEUTICALS, 160 SECOND STREET, CAMBRIDGE MA 02142
Christoffel Boshoff officer: Executive Vice President 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Jennifer B. Damico officer: SVP & Controller C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Payal Sahni officer: Executive Vice President ATTN: PFIZER CORP. SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Carapezzi William R Jr officer: Executive Vice President 600 MOUNTAIN AVENUE, MURRAY HILL NJ 07921
Douglas M Lankler officer: Senior Vice President PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Mikael Dolsten officer: Senior Vice President 5 GIRALDA FARMS, MADISON NJ 07940
David M Denton officer: Chief Financial Officer & EVP 1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117
William Pao officer: Executive Vice President C/O CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Michael Mcdermott officer: Executive Vice President C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, 235 EAST 42ND STREET NY 10017
Rady A Johnson officer: Executive Vice President PFIZER INC. ATTN CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Alexander R Mackenzie officer: Executive Vice President C/O PFIZER CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Sally Susman officer: Senior Vice President 767 FIFTH AVE, EOTIC LAWDER CORP, NEW YORK NY 10153
Angela Hwang officer: Group President 235 EAST 42ND STREET, ATTN: CORPORATE SECRETARY, NEW YORK NY 10017
John D Young officer: Business Unit President C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017

Pfizer (Pfizer) Headlines

From GuruFocus

Pfizer Inc at Wells Fargo Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc's Dividend Analysis

By GuruFocus Research 01-24-2024

Q1 2023 Pfizer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Pfizer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc at Citi BioPharma Conference Transcript

By GuruFocus Research 01-23-2024